Nephrology

The first quarter of 2025 saw approvals in diabetes, depression, kidney disease, and pain, among others. Read more about high-impact approvals of Q1 now.

The FDA accepted an sNDA for pegcetacoplan for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

The Biologics License Application submission for sibeprenlimab is supported by results from the phase 2 ENVISION and phase 3 VISIONARY clinical trials.

The new guideline provides healthcare providers, people living with ADPKD, and stakeholders with practical tools to improve diagnosis, care, and treatment.

The report acknowledges the global health challenge of CKD-MBD, and its effect on both skeletal and cardiovascular systems in people with CKD.

A trio of nephrology experts discuss the significance of iptacopan’s FDA approval as the first treatment for C3G.

The March 2025 approval for iptacopan marks the first for C3 glomerulopathy and is based on the APPEAR-C3G trial.

Lerma discusses the current treatment landscape for IgA nephropathy and what role APRIL inhibition may play in treating IgAN.

The submission is supported by results from the phase 3 DUPLEX Study and the phase 2 DUET Study in adult and pediatric patients with FSGS.

Patients with CKD undergoing radical prostatectomy for prostate cancer experienced greater rates of adverse in-hospital outcomes.

Retransplantation in elderly patients was associated with a higher risk of DWFG but similar death-censored outcomes to primary transplantation.

The Kidney Transplant Fast Track evaluation approach was associated with a higher likelihood of waitlisting and fewer disparities by race or ethnicity.

Psychosocial interventions reduced depressive symptoms in CKD but did not have a significant impact on patients’ quality of life.

Kidney transplant recipients who received a GLP-1 RA had a 49% lower incidence of death-censored graft loss and 31% lower mortality.

The FDA approved the sNDA for furosemide (Furoscix) to expand the indication to include treatment of edema in patients with CKD.

In part 2 of this episode of Crisis Point, 3 nephrology experts and a patient advocate discuss strategies to address the CKD crisis.

The nephrology month in review spotlights HCPLive’s coverage of renal trial developments, xenotransplant, new AKI guidance, and research about dialysis.

This FDA News Month in Review provides a round-up of regulatory decisions from February 2025.

The guidance is intended to inform the transition to outpatient care for patients with AKI-D and help care teams identify early signs of recovery.

Survey findings highlight pediatric nephrologists’ reluctance to list patients with kidney failure due to C3G or IC-MPGN for kidney transplantation.

From 1990-2021, the ASIR, ASMR, and age-standardized DALY rate of chronic kidney disease increased.

Low and high second-trimester eGFR values were linked to adverse pregnancy outcomes, including preeclampsia, preterm birth, low birth weight, and fetal loss.

Female dialysis patients had a greater risk of infection- and withdrawal-related mortality, while men were more likely to die from cardiovascular disease and cancer.

Greater levels of RC were linked to increased CKD risk and progression to ESRD in patients with type 2 diabetes-related kidney disease.

In the final segments of this 4-part episode, the discussion focuses on the use of HCEs in different kidney disease trials.